Le Lézard
Classified in: Health, Science and technology
Subjects: CCA, ACC

Invitation to presentation of BioInvent's second quarter report 2020 on August 27, 2020


LUND, Sweden, Aug. 21, 2020 /PRNewswire/ -- BioInvent International AB (OMXS: BINV) will issue its interim report for the second quarter 2020 on Thursday August 27 at 8.00 a.m. CEST, followed by an audiocast with teleconference at 5.30 p.m. CEST, hosted by Martin Welschof, CEO and members of the management team. The presentation will be held in English.

To participate, please call any of the following phone numbers from:

SE: +46 850558350

NE: +31 107129163

UK: +44 3333009266

US: +1 8335268398

Webcast: https://tv.streamfabriken.com/bioinvent-q2-2020

About BioInvent

BioInvent International AB (OMXS: BINV) is a clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of hematological cancer and solid tumors, respectively. Two preclinical programs in solid tumors are expected to have entered clinical trials by the end of 2020. The Company's validated, proprietary F.I.R.S.Ttm technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.

The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com.

For further information, please contact:

Martin Welschof, CEO      

Hans Herklots, LifeSci Advisors

+46 (0)46 286 85 50

+41 79 598 71 49

martin.welschof@bioinvent.com

hherklots@lifesciadvisors.com

BioInvent International AB (publ)

Co. Reg. No.: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50

www.bioinvent.com  

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

https://mb.cision.com/Main/583/3177602/1295401.pdf

Press release (PDF)

SOURCE BioInvent


These press releases may also interest you

at 02:00
Qi Card, the leading electronic banking solution and default national debit/credit card of Iraq has supported nearly one million Iraqis through a variety of credit options that power entrepreneurs, small businesses and personal spending, contributing...

at 01:00
Radsource, a leader in radiology clinical services and provider of Picture Archiving and Communication Systems (PACS), completed 9 installations of ProtonPACS for new customers in the third quarter of 2020. In the third quarter, Radsource installed...

24 oct 2020
ESSA Pharma Inc. , a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA's clinical candidate, EPI-7386, at the 32nd EORTC-NCI-AACR Annual...

24 oct 2020
Lianluo Smart Limited ("LLIT" or the "Company") , and privately-held Newegg Inc. ("Newegg") today jointly announced that they have entered into an Agreement and Plan of Merger (the "Merger Agreement"), whereby the stockholders of Newegg will become...

24 oct 2020
Leading online auto retailer Carvana announced today it will be the primary partner for 7-time NASCAR Cup Series (NCS) Champion Jimmie Johnson and Chip Ganassi Racing (CGR) for the 2021 NTT INDYCAR SERIES racing season in the newly-formed Carvana...

24 oct 2020
Compare-autoinsurance.org has launched a new blog post that explains how teen drivers can obtain cheaper car insurance in the United States. For more info and free car insurance quotes online, visit...



News published on 21 august 2020 at 07:04 and distributed by: